Clinical Trial Update: Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a combo of DEB-TACE, lenvatinib, and pucotenlimab as conversion therapy for unresectable intrahepatic cholangiocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• DEB-TACE
• Lenvatinib (lenvatinib)
• Pucotenlimab

Snippet

Sponsor: Tongji Hospital | Conditions: Cholangiocarcinoma Non-resectable | Phase 2 | Status: UNKNOWN